The disorders of purine metabolism illustrate the causation of human disease by molecular variants in the sense of different abnormal enzymes producing the same clinico-pathological manifesta- Purines are derived either from the diet or synthesized, mainly in the liver, from small molecular precursors. The biosynthetic source of the individual atoms of the purine ring and the steps in the biosynthetic sequence are shown in figures 1 and 2 respectively. The formation of fl-phosphoribosylamine from a-5-phospho-D-ribosyl-1-pyrophosphate ('phosphoribosylpyrophosphate' or 'PRPP') and glutamine is the first reaction which is specific to purine biosynthesis. It is catalysed by phosphoribosylpyrophosphate amidotransferase [ribosylamine-5'-phosphate pyrophosphate phosphoribosyltransferase (glutamate amidating) EC 2.4.2.14] and is the rate-limiting step on the metabolic pathway. Variations in the activity of this reaction are brought about by the availability of PRPP and through a series of feedback controls by the purine ribonucleotides which are the end products of the biosynthetic sequence. Recent evidence indicates that these factors operate by altering the subunit structure of the enzyme, PRPP converting the enzyme to the catalytically active monomeric form (molecular weight 133 000), and purine ribonucleotide promoting aggregation of the enzyme subunits into a dimeric form (molecular weight 270 000) which is catalytically inactive. Mammalian liver is a relatively poor starting material for the preparation of phosphoribosyl amidotransferase and the catalytic and kinetic properties of the enzyme were studied in detail by Holmes and his colleagues
The disorders of purine metabolism illustrate the causation of human disease by molecular variants in the sense of different abnormal enzymes producing the same clinico-pathological manifestations and of different inherited anomalies of the same enzyme protein resulting in the same clinical manifestations. Except for the clinical recognition of tophaceous gout and uric acid urinary stones, an abnormal concentration of uric acid in the blood or urine is the usual indicator of an abnormality in this area of metabolism, and the serum uric acid is usually measured in routine biochemical profiles. The methods of measuring uric acid in biological fluids were recently reviewed by Watts (1974a) . Those Purines are derived either from the diet or synthesized, mainly in the liver, from small molecular precursors. The biosynthetic source of the individual atoms of the purine ring and the steps in the biosynthetic sequence are shown in figures 1 and 2 respectively. The formation of fl-phosphoribosylamine from a-5-phospho-D-ribosyl-1-pyrophosphate ('phosphoribosylpyrophosphate' or 'PRPP') and glutamine is the first reaction which is specific to purine biosynthesis. It is catalysed by phosphoribosylpyrophosphate amidotransferase [ribosylamine-5'-phosphate pyrophosphate phosphoribosyltransferase (glutamate amidating) EC 2.4.2.14] and is the rate-limiting step on the metabolic pathway. Variations in the activity of this reaction are brought about by the availability of PRPP and through a series of feedback controls by the purine ribonucleotides which are the end products of the biosynthetic sequence. Recent evidence indicates that these factors operate by altering the subunit structure of the enzyme, PRPP converting the enzyme to the catalytically active monomeric form (molecular weight 133 000), and purine ribonucleotide promoting aggregation of the enzyme subunits into a dimeric form (molecular weight 270 000) which is catalytically inactive. Mammalian liver is a relatively poor starting material for the preparation of phosphoribosyl amidotransferase and the catalytic and kinetic properties of the enzyme were studied in detail by Holmes and his colleagues (Holmes, McDonald, McCord, Wyngaarden, and Kelley, 1973; using enzyme isolated from human placenta. These studies extended results of earlier investigations on the pigeon liver enzyme (Caskey, Ashton, and Wyngaarden, 1964 ; Rowe and Wyngaarden, 1968;  Rowe, Coleman, and Wyngaarden, 1970) . The recently reported properties of human glutamine phosphoribosylpyrophosphate amidotransferase are presented in table I. Wood and Seegmiller (1973) studied the phosphoribosylpyrophosphate amidotransferase activity of extracts from human lymphoblasts and report that PRPP and purine ribonucleotides compete with one another for binding to the enzyme.
Molecular variation in relation to purine metabolis4n Watts, 1966 and by permission of the pi hyperuricaemia and hyperuricaciduria Fructose loading does not affect the bloo uric acid levels in essential fructosuria du kinase (ATP: D-fructose 6-phosphotransferase EC 2.7.1.4) deficiency, whereas marked changes are observed in hereditary fructose intolerance due to GLYCINE phosphofructoaldolase (fructose-1 ,6-diphosphate Dglyceraldehyde-3 phosphate lyase EC 4.1 .2.b). Fructose-induced hyperuricaemia may result from several different physiological effects including rapid degradation of adenine nucleotides (Maenpaa, Raivio, and Kekomaki, 1968; Fox and Kelley, 1972) . The reduced rate of purine biosynthesis de novo produced by drugs such as allopurinol, orotic acid, and adenine which react with PRPP in vivo are at least partly due to their lowering of the intracellular concentration of the latter compound. Direct evidence suggesting the converse situation in vivo is lacking, except in the case of uric acid overproduction associated with excessive PRPP synthesis, which is discussed below. individual
The PRPP synthesis is catalysed by PRPProm synthetase (ATP:D-ribose-5-phosphoribosyltransferwblishers).
ase EC 2.7.6.1.). Kinetic studies have revealed an ordered bi-bi mechanism for the reaction, the ribose-5-phosphate (R5P) binding first followed by binding l in man. of Mg2+-ATP, release of AMP and finally release of od or urine PRPP. The enzyme shows reversible association and ie to fructo-dissociation with estimated molecular weights of 
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The combination of 6-OH and 6-NH2 purine ribonucleotides produces synergistic inhibition.
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Pyrimidine ribonucleotides inhibit the enzyme to a lesser extent than purine nucleotides. Neither class of nucleosides and bases is inhibitory. 6 Purine ribonucleotides inhibit the enzyme in a manner which is competitive with respect to PRPP but non-competitive with respect to glutamine and change the substrate velocity curve for PRPP, but not glutamine, from a hyperbolic to a sigmoidal function. 7
The enzyme exists in two interconvertible forms with molecular weights of 133 000 and 270 000 respectively.
8
Purine ribonucleotides convert the small to the large form of the enzyme as well as inhibiting the enzyme. 9 PRPP dissociates the large form of the enzyme into the small form as well as reversing nucleotide inhibition. Table 1 The properties of human placental phosphoribosylpyrophosphate amidotransferase [ribosylamine-S'-phosphate pyrophosphate phosphoribosyltransferase (glutamate amidating) EC 2.4.2.14] the native forms of the enzymes varying between 60 000 and 1 200 000. The aggregated form of the enzyme, which occurs in the presence of 0 3 mmol/l ATP and 6 mmol/l Mg2+ appears to be the active and most stable form. The activity of the enzyme is regulated by the following factors: (1) ADP which inhibits competitively with respect to ATP: (2) inhibition by 2,3-diphosphoglycerate (2,3-DPG) and PRPP; (3) non-competitive inhibition by other nucleotides . Reem (1972) investigated purine biosynthesis de novo in human spleen cells and in Burkitt lymphoma cells. She found that these tissues not only contained an active phosphoribosylpyrophosphate amidotransferase but that ammonia could replace glutamine and that phosphoribosylamine (PRA) was formed by an alternative pathway directly from R5P and ammonia. The latter reaction was catalyzed by an enzyme which could be separated from phosphoribosylpyrophosphate amidotransferase, and it was also subject to inhibition by the endproducts of the purine synthetic pathway, particularly by AMP and to a lesser extent by GMP. These results agreed with earlier findings in cell-free extracts of leukaemic mouse spleens. They open up the possibility that an alternative mechanism beginning with the reaction of R5P and ammonia may contribute to overall purine biosynthesis de novo, and that the regulation of the rate of purine biosynthesis may be more complex than was formerly thought, depending on the control of two alternative pathways rather than a single rate-limiting reaction for the synthesis of 3-phosphoribosylamine. It should also be noted that R5P is one of the substrates of PRPP synthetase and the formation of P-phosphoribosylamine from R5P plus ammonia would reduce the substrate availability for PRPP synthesis, increasing further the possibility for the interplay of control mechanisms.
Inosine-5'-phosphate (inosinic acid) is formed from /3-phosphoribosylamine by the sequence of reactions shown in figure 2. The individual enzymes have been less fully studied in relation to human biochemistry, although they clearly offer other points at which control mechanisms could operate to influence the rate of purine biosynthesis de novo.
PURINE SALVAGE PATHWAYS
Free purine bases of dietary or endogenous origin are converted directly to the corresponding purine-5'-monophosphate by the purine phosphoribosyltransferase ('pyrophosphorylase') enzymes. These are the so-called purine salvage pathways. Adenine phosphoribosyltransferase or APRT (AMP: pyrophosphate phosphoribosyltransferase EC 2.4.2.7) catalyzes the production of adenosine-5'-phosphate (AMP) from adenine and PRPP. Hypoxanthine guanine phosphoribosyltransferase or HGPRT (IMP: pyrophosphate phosphoribosyltransferase EC 2.4.2.8) catalyzes the formation of guanosine-5'-phosphate (GMP) and inosine-5'-phosphate (IMP) from guanine and hypoxanthine respectively. Hypoxanthine guanine phosphoribosyltransferase also converts xanthine to xanthosine-5'-phosphate (XMP); this reaction occurs much more slowly than the corresponding reactions with guanine and hypoxanthine. The drugs 6-mercaptopurine, 8-azaguanine, 6-thioguanine, azathioprine, and allopurinol are also converted to their corresponding ribonucleotides by HGPRT. Other specific phosphoribosyltransferases catalyze the reactions of PRPP with orotic acid and nicotinic acid. Arnold and Kelley (1973) have purified human HGPRT to homogeneity (8000 fold) and find that it has a molecular weight of 68 000 and is composed of two subunits of equal molecular weight (34 000). They also demonstrated three electrophoretically distinct variants which they concluded were due to non-genetic posttranslational alterations of the enzyme protein. Craft, Dean, Watts, and Westwick (1970) investigated some of the kinetic properties of this enzyme and reported results which were compatible with the enzyme having allosteric properties, and hence with its having a regulatory role by virtue of its effect on the supply of IMP and GMP which influence the activity of the rate-limiting initial step on the purine biosynthetic pathway de novo. Gutensohn (1973) purified HGPRT from rat brain tissue and found that it resembled the human erythrocyte enzyme closely. Most of the enzyme was present in the soluble fraction of the brain, although the synaptosomes contained a small but significant amount.
The purine salvage pathways are of particular importance in tissues which have a high requirement for purines but low activity with respect to purine synthesis de novo. The bone marrow and brain belong to this category, whereas liver has high activities for both purine synthesis de novo and purine salvage. The quantitative significance of muscles as a source of purine during exercise is not known. The deamination of AMP to IMP is catalyzed by AMP deaminase (AMP: aminohydrolaseEC3.5.4.6.): this reaction occurs during anaerobic muscle contraction and the IMP is further converted to inosine and hypoxanthine. The increased hypoxanthine and xanthine excretion during muscular work was documented by Nasrallah and Al-Khalidi (1964) . In addition, although uric acid excretion decreases during severe exertion, there is a net increase in uric acid excretion during the 48-72-hour period after the beginning of which exertion was undertaken (Cathcart, Kennaway, and Leathes, 1908) .
Erythrocytes have high purine phosphoribosyltransferase activities and this may be related to their function in respect of purine ribonucleotide transport. The overall biological significance of the purine salvage pathways has been ably reviewed by Murray (1971) . Erythrocytes contain active transport systems for both purine bases and nucleosides. It is thought that the purine ribonucleotides which are the product of purine biosynthesis de novo are converted to nucleosides under the influence of the 5'-nucleotidase (5'-ribonucleotide phosphohydrolase EC 3.1.3.5) attached to the hepatocyte plasma membrane. The nucleoside is further degraded to the free base by nucleoside phosphorylase, and is then converted to ribonucleotide by the erythrocyte phosphoribosyltransferase. It is uncertain if the nucleoside phosphorylase acts before or after the purine enters the red cell. The reverse reactions are also believed to occur in the tissues to which purines are transported.
PURINE RIBONUCLEOTIDE INTERCONVERSION REACTIONS
Inosinic acid is converted to guanosine-5'-phosphate (guanylic acid) and to adenosine-5'-phosphate (adenylic acid) by the ribonucleotide interconversion reactions which are shown together with the purine salvage pathways and the steps which lead to uric acid in figure 3.
Each of these reactions is enzymatically catalyzed, but although they have been well studied, there are relatively few observations which relate specifically to human disease or biochemical pharmacology. Holmes, Pehlke, Leyva, and Kelley (1973) have studied inosinic dehydrogenase (IMP :NAD+ oxidoreductase EC 1.2.1.14). Assayable amounts of the enzyme were present in human fibroblasts growing in tissue culture, and the enzyme was isolated from human placenta. These authors showed that the activity of the enzyme is regulated by the end products of purine biosynthesis and that it could be another point on the purine biosynthetic pathway at which some drugs and their metabolic products, eg, allopurinol, 6-mercaptopurine, mycophenolic acid, exert their pharmacological effects.
Xanthine oxidase (xanthine oxygen: oxidoreductase EC 1.2.3.2) is of particular clinical interest, its inhibition being the overriding effect when allopurinol is given therapeutically to control hyperuricaemia and hyperuric aciduria. It occurs mainly in liver, milk, and small intestinal mucosa. The molecular weight is about 300 000 and it can be dissociated into two subunits of 150 000 molecular weight. It contains 2 atoms of molybdenum, 2 flavin adenine dinucleotide (FAD) residues, 8 atoms of non-haem iron, and 8 moles of labile sulphur per molecule. The mechanism of action is complex so that the enzyme itself forms a respiratory chain. The electron flow occurs sequentially from substrate to molybdenum which is reduced from the Mb(VI) to the Mb(V) oxidation state, to FAD, to iron and finally to molecular oxygen. The enzyme can function as a dehydrogenase using NAD+ as the terminal electron acceptor, a conformational change (from so-called 'D' to 'O' form) accompanies. the change in receptor specificity and this occurs on storage of the liver enzyme at -20°C (Corte and Stirpe, 1968; . The relative activity of the: enzyme as an oxidase or a dehydrogenase varies between different species, and the enzyme itself has a wide substrate specificity which includes aldehydes, pteridines, purine analogues, and purines other than hypoxanthine and xanthine. The two-step oxidation of hypoxanthine involves release of xanthine and rebinding of this second substrate to a possibly different active site.
Human tissues lack uricase (urate: oxygen oxidoreductase EC 1.7.3.3) but one third of the uric acid which is produced in man is destroyed by other uricolytic mechanisms, eg, peroxidatively, or excreted into the gut where it is degraded by bacterial action.
URIC ACID TRANSPORT
The low solubilities of uric acid and its salts are responsible for the clinical manifestations of gout. The plasma uric acid is mainly in the form of urate and the solubility is that of monosodium urate, about 7 mg/100 ml (theoretical value = 6-4 mg/ 100 ml). Urate binds reversibly to serum albumin as well as to the specific urate binding OX1-2 globulin, and plasma is readily supersaturated with sodium urate in vitro, and presumably also in vivo, concentrations as high as 90 mg/100 ml having been observed during the treatment of myeloproliferative diseases. Drugs such as aspirin and phenylbutazone, and the fatty acids and bilirubin, reduce the plasma protein binding of urate (Klinenberg and Kippen, 1970; Klinenberg, Bluestone, Campion, and Whitehouse, 1973) . These workers also report that about 20% of the serum urate is bound to serum albumin (5 g/100 ml) at free urate concentrations between 1 and 12 mg/100 ml. High levels of the urate-binding Ml1-2 globulin were reported in some patients with myeloproliferative diseases (Alvsaker, 1966) , and inherited low levels of urate binding Ml1-2 globulin are sometimes a factor influencing the occurrence and severity of gout in hyperuricaemic individuals (Alvsaker, 1968; Alvsaker and Seegmiller, 1972) . The renal handling of urate has been reviewed by Milne (1966) and by Steele (1971) . The overall renal clearance is about one tenth of the glomerular filtration rate, ignoring any possible effect of plasma binding. This value is attained by the age of 6 months, the urate clearance being about 35 % of the glomerular filtration rate during the first weeks of life (Passwell, Boichis, Orda, and Brish, 1973) . It has been generally accepted that the filtered urate is virtually completely reabsorbed in the more proximal part of the nephron and that the excreted urinary uric acid has been excreted into the distal region of the nephron. However, Diamond and Sharon (1973) have presented evidence for the existence of a postsecretory reabsorptive site for uric acid in man, and that the renal tubular secretion of urate may greatly exceed the uric acid excretion. A wide range of drugs influences the active transport of uric acid across the renal tubular epithelium and this effect can markedly affect the plasma and urinary urate levels. The same drugs produce uricosuria or favour urate retention depending on the dose administered, and the result seen at the clinical level depends on the relationship of the usual therapeutic dose to the uricosuric and urate-retaining doses respectively. Kramp, Lassiter, and Gottschalk (1971) , using micropuncture and micro injection techniques, obtained data which were compatible with the operation of a carrier-mediated mechanism for urate reabsorption, and which was probably located at the luminal border of the proximal tubule epithelium.
Gout
Gout is the syndrome which results from crystallization of monosodium urate from supersaturated body fluids in vivo. This may be due to overproduction or underexcretion of uric acid or to the combination of both of these factors (Seegmiller, Grayzel, Laster, and Liddle, 1961; Seegmiller, Grayzel, Howell, and Plato, 1962; Rieselbach, Sorensen, Shelp, and Steele, 1970) . The synovial membranes of joints, bursae, and tendon sheaths are favoured sites for the crystallization so that the rheumatological manifestations of the disease dominate the clinical picture. Urinary stones, usually pure uric acid, occur in 10-25% of gout patients; this is more than 1000 times the incidence in the general population (Gutman and Yu, 1968) . Renal damage by interstitial deposits of monosodium urate occurs, usually mainly in the renal pyramids and produces segmental loss of kidney tissue. Proteinuria and hypertension occur in 10-40% of gout patients Talbott and Terplan, 1960 Other mutations of HGPRT are encountered which leave the enzyme with more residual catalytic activity. These patients also present with severe juvenile gout, uric acid urolithiasis but have inconstant and only minor neurological manifestations with mild degrees of mental retardation. The extent to which these cases of incomplete HGPRT deficiency contribute to the gouty population as a whole is uncertain, but it is unlikely to be more than about 1 % of all cases (Delbarre, Cartier, Auscher, de Gery, and Hamet, 1970; Boyle, Greene, and Seegmiller, 1971; Yii, Balis, Krenitsky, Dancis, Silvers, Elion, and Gutman, 1972) . Increasing experience has shown that the syndromes of 'complete' HGPRT deficiency (Lesch-Nyhan syndrome) and 'incomplete' HGPRT deficiency form a continuum, and the degree of neurological deficit does not parallel the HGPRT level at least as measured in erythrocytes (Emmerson and Thompson, 1973) (Becker, Mayer, Wood, and Seegmiller, 1973; (Strand, Felsher, Redeker, and Marver, 1970 (Alepa, Howell, Klinenberg, and Seegmiller, 1967; Jakovcic and Sorensen, 1967; Kelley, Rosenbloom, Seegmiller, and Howell, 1968 ) and urate retention due to the abnormal organic acidaemia which occurs in this disorder (Yu, Sirota, Berger, Halpern, and Gutman, 1957; Goldfinger, Klinenberg, and Seegmiller, 1965 ). Glucose-6-phosphatase catalyzes the hydrolysis of D-glucose-6-phosphate to D-glucose and phosphate. It also cleaves inorganic pyrophosphate hydrolytically and catalyzes the formation of D-glucose-6-phosphate from inorganic pyrophosphate and glucose (Stetten and Taft, 1964) . The purine overproduction in type I glycogen storage disease can be explained as follows. Deficiency of glucose-6-phosphatase leaves more glucose-6-phosphate available for metabolism via the phosphogluconate (pentosephosphate) shunt pathway with increased generation of ribose-5-phosphate, the substrate for PRPP synthetase. The increased availability of PRPP favours the disaggregation of phosphoribosylpyrophosphate amidotransferase subunits so that the rate of purine synthesis de novo is increased.
INCREASED GLUTATHIONE REDUCTASE ACTIVITY
Hyperuricaemia and gout are also associated with the increased glutathione reductase (NADPH: glutathione oxidoreductase EC 1.6.4.2) activity which accompanies the presence of an electrophoretically fast moving variant of this enzyme (Long, 1967 (Kelley and Meade, 1970; Bakay and Nyhan, 1971; Arnold, Meade, and Kelley, 1972; Arnold and Kelley, 1973) . Molecular heterogeneity between different patients with the syndrome has been demonstrated on the basis of the kinetic properties and heat inactivation curves of the enzyme in blood cells and cultured fibroblasts (McDonald and Kelley, 1971; Kelley and Meade, 1970) . The mutant gene is inherited in a sex-linked manner: the affected males do not reproduce, so that one third of the cases are expected to arise from fresh mutations. Experimental evidence for the occurrence of a case as a result of a fresh mutation was presented by McKeran, Andrews, Howell, Gibbs, Chinn, and . It has been widely accepted that lack of HGPRT activity reduces the availability of phosphoribosylpyrophosphate amidotransferase (Seegmiller, Rosenbloom, and Kelley, 1967) . The recent studyofHolmes, The macrocytic anaemia which accompanies the Lesch-Nyhan syndrome can be corrected by giving adenine. This phenomenon, together with the observation that the fibroblasts from these patients grow better in vitro when the culture medium contains added adenine and folate, suggested that these agents, particularly adenine, might improve the neurological manifestations. This has not proved to be so, even when adenine was given from the first week of life (Schulman, Greene, Fujimoto, and Seegmiller, 1971) , except in the case reported by Demus, Kaiser, and Schaub (1973) , who claim some symptomatic improvement. The interpretation of these therapeutic studies is difficult, unless, as in the study of Schulman, Greene, Fujimoto and Seegmiller (1971) (Kelley, Greene, Rosenbloom, Henderson, and Seegmiller, 1969) . The brain damage has been ascribed to the toxic action of the oxypurines, to some other unidentified metabolite, or to failure to conserve purine bases, particularly GMP in the brain. This organ has a low capacity for purine biosynthesis de novo and is heavily dependent on purine salvage pathways. McKeran, Howell, Andrews, Watts, and Arlett (1974) present evidence which suggests that HGPRT deficiency may cause impaired proliferation of brain cells during the perinatal growth spurt and that this is a factor in the development of brain damage. Adams' (1973) (Gutensohn and Guroff, 1972 The brain glycoproteins contain mannose and N-acetyl glucosamine linked to a polypeptide chain through asparagine residues, and the carbohydrate moiety of the molecule is completed by adding mannose, N-acetyl glucosamine, sialic acid, and fucose residues. Interference with either peptide or glycoprotein synthesis during the critical period of brain growth would be expected to produce profound neurological sequelae. However, Nyhan (1973) still favours the toxic factor hypothesis by analogy with the experimental production of selfmutilative gnawing in rats and rabbits given 1,3,7-methylpurine or 1,3-methylpurine but not 3,7-methylpurine. Although the cerebrospinal fluid levels of hypoxanthine are increased in the Lesch-Nyhan syndrome, higher levels are observed in xanthinuria (congenital xanthine oxidase deficiency) in which there is no neurological dysfunction, and this suggests that at least hypoxanthine is not responsible for the brain damage. Sweetman and Nyhan (1970) report that the patients excrete increased amounts of 5-amino-4-imidazole carboxamide (AIC), AICriboside, hypoxanthine and xanthine, with decreased excretion of adenine and adenosine. These changes presumably reflect the accelerated purine biosynthesis de novo and lack of IMP which is the precursor of AMP via adenylosuccinate (fig 2) .
The activity of red cell APRT is increased in the Lesch-Nyhan syndrome. It has been suggested that this is due to stabilization of the enzyme by the abnormally high intracellular concentration of PRPP which protects the enzyme from decrease in activity as the cells become older.
Fibroblast cultures prepared from the mothers of the affected boys contain two populations of cells, those with HGPRT (HGPRT+) and those which lack the enzyme (HGPRT-). The numbers of HGPRT+ and HGPRT-cells are not exactly equal as would be predicted by the Lyon hypothesis of random inactivation of the X chromosome, and this inequality has been explained as being due to metabolic cooperation'. The blood cells do not show mosaicism and there is evidence that this is due to impaired growth of HGPRT-blood cell precursors so that the clones of defective cells are bred out and ultimately overgrown by cells derived from the clones of HGPRT+ cells. This conclusion is based on the study of a family in which the abnormal genes for both HGPRT deficiency and glucose-6-phosphate dehydrogenase deficiency were segregating (Nyhan, Bakay, Connor, Marks, and Keele, 1970; Nyhan, 1973) , and on studies of the growth of bone marrow progenitor cells from heterozygotes and affected hemizygotes for complete HGPRT deficiency (Lesch-Nyhan syndrome) in tissue culture (McKeran, Andrews, Howell, Gibbs, Chinn, and . Conversely, other studies have shown the expected mosaicism among the bone marrow cells of a heterozygote for the partial HGPRT deficiency and in her jejunal mucosa (McKeran, Andrews, Howell, Gibbs, Chinn, and .
Hair follicles display some degree of clonal growth and the property can be used to identify the female carriers of the disorder by virtue of the mosaicism of their hair follicles with respect to the presence of HGPRT in the follicle cells (Gartler, Scott, Goldstein, Campbell, and Sparkes, 1971; Silvers, Cox, Balis, and Dancis, 1972; Francke, Bakay, and Nyhan, 1973; .
It is possible to establish the genetic status of the fetus of the female carriers of the abnormal gene by studies on cultured amniotic fluid cells, and this has now been of practical value in the management of several women who have previously borne a child with the Lesch-Nyhan syndrome (Fujimoto, SeegMiller, Uhlendorf, and Jacobson, 1968; DeMars, Sarto, Felix, and Benke, 1969; Boyle, Raivio, Astrin, Schulman, Graf, Seegmiller, and Jacobsen, 1970; Watts, 1974b 
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HGPRT locus were used by Subak-Sharpe (1969) in the studies on which he based the concept of metabolic cooperation. Cells which lack HGPRT can grow in the presence of concentrations of azaguanine or 6-mercaptopurine which are lethal to normal cells because they do not convert the drug to its toxic ribonucleotide. The use of selective tissue culture media permits selection for either HGPRT+ or HGPRT-cells. They can be used to study spontaneous mutation rates, to test the effects of mutagenic compounds on the mutation rate, and for cell hybridization studies. The use of HGPRT-human cells derived from cases of the Lesch-Nyhan syndrome for the study of somatic cell genetics in man is briefly reviewed by Nyhan (1973) .
Other Presumably Genetically Determined Conditions with Excessive Purine Biosynthesis
Hooft, van Nevel, and de Schaepdryver (1968) described a girl who clinically resembled cases of the Lesch-Nyhan syndrome, in whom purine biosynthesis de novo was accelerated but who was normouricaemic. Her parents were first cousins. This child clearly suffered from a disorder of purine metabolism which differed from the Lesch-Nyhan syndrome. Unfortunately HGPRT was not measured.
A patient with another apparently inherited disorder of purine metabolism was reported by Nyhan, James, Teberg, Sweetman, and Nelson (1969) . This boy failed to thrive and was found to be grossly hyperuricaemic when he was 4 months old. He was mentally retarded and autistic by the age of 3 years. His teeth were dysplastic and he failed to cry with tears. Purine biosynthesis de novo was accelerated, HGPRT was normal, but APRT was increased.
Deficiency of AMP: Pyrophosphate Phosphoribosyltransferase (EC 2.4.2.7) (APRT) Partial deficiency of this enzyme (activity of erythrocytes between 21 and 37 % of normal) was reported by Kelley, Levy, Rosenbloom, Henderson, and Seegmiller (1968) in four members over three generations of one family. The subjects were all asymptomatic and had no abnormality of purine metabolism, although the propositus also had type III hyper-,Blipoproteinaemia as a coincidental finding. These authors concluded that the condition was probably due to the operation of a mutant autosomal gene. Fox, Meade, and Kelley (1973) have described a second family with eight affected members over three generations. In this family the propositus also had hyperuricaemia, but the reduced APRT activity and the latter trait appeared to segregate independently in the family. The levels of APRT activity in the erythrocytes were similar to those observed in the first family studied, but Fox, Meade, and Kelley (1973) found that the activities of this enzyme in the leucocytes and cultured fibroblasts were normal. They were able to show that the residual APRT activity had normal heat stability and a normal half life in vivo. There was no detectable abnormality in purine metabolism, erythrocyte PRPP and ATP concentrations were normal, the response to an intravenous infusion of fructose (this assesses adenine nucleotide availability in vivo) was normal, and there was a normal response to adenine administration.
Xanthinuria
The blood and urine uric acid levels are strikingly low in xanthinuria, less than about 1 0 mg/100 ml and about 50 mg/24 hours when the patient is taking an unrestricted diet, and the analyses are made by one of the currently routine colorimetric methods. The results of determinations made when the patient is taking a purine-free diet and using a differential spectrophotometric enzymatic method are usually lower, less than 05 mg/100 ml and 15 mg/24 hours respectively. The cases which had been reported before 1972 were recently summarized by Watts (1972) , and although there have been some more recent case reports and family studies (CastroMendoza, Cifuentes Delatte, and Rapado Errazti, 1972; Frayha, Salti, Haidar, Al-Khalidi, and Hemady, 1973; Holmes, Mason, and Kelley, 1973; Auscher, Pasquier, Mercier, and Delbarre, 1973; Wilson and Tapia, 1973) , it is improbable that all of the identified cases are reported in the literature now that the syndrome has been well publicized.
The concentrations of hypoxanthine and xanthine in the plasma and urine are increased to about 0Q5-0Q9 mg/100 ml in the case of plasma and to about 100-600 mg/24 hours in the case of urine. These results are expressed as total oxypurines, ie, the sum of hypoxanthine and xanthine; the latter compound accounts for about 60-90 % of the total oxypurines, although the exact proportion is different in individual cases. Low concentrations of oxypurines are sometimes found in normal plasma (0-0-0-25 mg/100 ml) and hypoxanthine is the main component. Blood samples which are to be analysed for oxypurines should be chilled to 0 C immediately they are drawn and centrifuged at 0-4°C without delay in order to minimize hypoxanthine leakage from the erythrocytes. The normal urinary excretion of oxypurines is approximately 11-22 mg/24 hours and there is a slight excess of hypoxanthine. The oxypurines are most conveniently determined by differential spectrophotometric enzymatic methods (Chalmers and Watts, 1968; . Holmes, Mason, and Kelley (1973) reported that giving allopurinol to a patient with xanthinuria reduced the ratio xanthine/hypoxanthine in the urine from 6.69 to 0-27 without changing the total purine excretion. Disregarding any possible effect of the drug or its metabolites on the renal tubular handling of the oxypurines, this suggests that there was rather more residual xanthine oxidase catalytic activity with respect to the oxidation of hypoxanthine to xanthine than of xanthine to uric acid.
Most cases of xanthinuria are asymptomatic and the characteristic low uric acid levels are found during investigation for another disease. About one third of the reported cases have presented with xanthine stones, which are radiotranslucent. Two patients have been reported in whom a myopathy was associated with intramuscular hypoxanthine and xanthine crystals (Chalmers, Watts, Pallis, Bitensky, and Chayen, 1969; . These patients began to experience muscle pain and stiffness when they were about 30 years old (Chalmers, Johnson, Pallis, and Watts, 1969) . The increased concentrations of hypoxanthine and xanthine in the muscle biopsies was also demonstrated by means of an integrated ion current technique with the high resolution mass spectrometer. Only a few milligrams of dessicated tissue were needed for these measurements .
The results of family studies are compatible with the affected individuals being homozygous for a rare autosomal recessive mutant gene. Some of the presumably heterozygousindividualsexcreteamounts of oxypurines which are intermediate between the normal range and the amounts excreted by patients with xanthinuria. Their blood or urine uric acid levels are normal. Other presumably heterozygous subjects excrete normal amounts of oxypurines as well as uric acid. The reported cases of xanthine urolithiasis with normal urinary excretion of uric acid which date from the period before congenital xanthine oxidase deficiency (xanthinuria) was recognized may have been the heterozygous carriers.
The metabolic lesion has been demonstrated in liver tissue, jejunal mucosa, and in colostrum, and prevents the oxidation of both hypoxanthine and xanthine. The drug allopurinol [4-hydroxypyrazolo (3,4-d)pyrimidine] is a structural isomer of hypoxanthine, and is oxidized to the xanthine isomer oxipurinol [4,6-dihydroxypyrazolo (3,4-d) pyrimidine]. Chalmers, Parker, Simmonds, Snedden, and Watts (1969) reported the excretion of oxi-purinol by a patient with xanthine oxidase deficiency who was taking allopurinol. Ausher, Pasquier, Mercier, and Delbarre (1973) have confirmed this observation and reported the analogous oxidation of 4-thio-pyrazolo-pyrimidine (thiopurinol), the rate of excretion of the oxidation products being the same in xanthinuric and non-xanthinuric subjects. It seems likely that this represents oxidation of the drug by aldehyde oxidase (aldehyde: oxygen oxidoreductase EC 1.2.3.1) (Johns, Spector, and Robins, 1969) rather than metabolism of allopurinol via oxidation of its ribonucleotide analogue, as originally suggested by Chalmers, Parker, Simmonds, Snedden, and Watts (1969) . Aldehyde oxidase is an iron, molybdenum and coenzyme-Qio, containing flavoprotein (Rajagopolan, Fridovich, and Handler, 1962) , which is distinct from xanthine oxidase with which it has sometimes been confused. Elion, Kovensky, Hitchings, Metz, and Rundles (1966) found that a xanthinuric patient did not excrete oxipurinol when given allopurinol. The validity of this observation was questioned by later workers on the grounds that the drug had not been given for a sufficiently long period for this effect to have become manifest. However, Holmes, Mason, and have recently reported another patient in whom allopurinol was apparently not oxidized to oxipurinol. Further work is needed to establish the cause of this apparent heterogeneity in the disorder, with particular attention being paid to the level of residual activity for the oxidation of hypoxanthine to xanthine, the activity of aldehyde oxidase, and the pharmacodynamics of allopurinol in these patients.
The renal clearance of the oxypurines (hypoxanthine plus xanthine) is increased to about 80 % of the glomerular filtration rate in xanthinuria due to the increased filtered load of oxypurines (Goldfinger, Klinenberg, and Seegmiller, 1965) . Hypoxanthine and xanthine are cleared by the kidneys at about the same rate and appear to be both reabsorbed and secreted by the renal tubules (Chalmers, Johnson, Pallis, and Watts, 1969 (Cleaver, 1971) . The biochemical abnormality can now be positively identified during life (Epstein, Fukuyama, and Epstein, 1969) and in the fetus before birth (Regan, Setlow, Kaback, Howell, Klein, and Burgess, 1971) . This should facilitate the clinical differentiation from the dominantly inherited 'basal cell naevus' syndrome (Binkley and Johnson, 1951) in which the naevi are associated with dental cysts, skeletal abnormalities, and sometimes mental retardation, and from Bloom's syndrome (photosensitivity, skin malignancies, and increased chromosome breaks) (German, 1969) .
There have been no studies to assess the effect of this metabolic lesion on the rate of purine biosynthesis or the dynamics of uric acid metabolism, although widespread hyperplastic skin lesions in psoriasis are associated with secondary changes in these parameters (Eisen and Seegmiller, 1961) .
Defects in the Renal Handling of Uric Acid
Reduced uric acid excretion in the presence of a normal rate of uric acid production appears to underlie some cases of essential hyperuricaemia and gout.
Glomerular function is not demonstrably altered so this presumably relates to an imbalance between renal tubular reabsorption and secretion, although its molecular basis has not been defined. Hyperuricaemia occurs in a diversity of disorders where, in the absence of increased uric acid biosynthesis de novo (urate overproduction) or a glomeruler lesion it is ascribed to the effect of the primary pathological process on the renal tubular transport mechanisms for urate. Primary hyperparathyroidism (Scott, Dixon, and Bywaters, 1964) and essential hypertension (Breckenridge, 1966) An apparently isolated renal tubule reabsorption defect with hypouricaemia was reported in an apparently healthy young man by Praetorius and Kirk (1950) . Plasma uric acid values were in the range 0-2-0-6 mg/100 ml with urinary excretion of about 700 mg/24 hours. Uric acid clearances ranged from 162 to 284 ml/min (normal = 7 to 10 ml/min). The original report of increased plasma oxypurine levels in this case appears to have been due to breakdown of erythrocyte ribonucleotides before the plasma was separated from the erythrocytes. Simkin, Skeith, and Healey (1973) have reported another similar case and do not mention any changes in oxypurine levels. They showed that pyrazinamide, salicylate, and probenecid all inhibited the urate secretion, and they concluded that the biphasic effect of uricosuric drugs in normal subjects must result from independent and antagonistic action on separate secretory and reabsorptive systems.
Conclusions
The clinical and biochemical effects of identified molecular variants of the enzymes which catalyze purine biosynthesis, salvage, and degradation and excretion have been described as far as they are known. Purine biosynthesis, salvage and degradation are geared to maintaining the supply ofpurine nucleotides for: (1) DNA and RNA biosynthesis; (2) the production of the high energy triphosphates; (3) for certain coenzymes. It seems reasonable to suggest that other metabolic lesions will be identified in this area of metabolism, particularly if alternative metabolic pathways are possible so that the mutation would not be lethal, or if they are of a type which acts by altering the concentration or availability of a regulatory substrate. Mutations involving the polymerization of nucleotides to form DNA and RNA would presumably be incompatible with any embryonic development. However, it is of interest that a mutation of the endonuclease responsible for the repair of DNA is recognizable in association with a disease entity characterized by malignant disease which can be associated with a specific cause of damage to nuclear material. The extent to which genetic factors participate in the multifactorial aetiology of malignant disease in general remains a problem for future study.
